Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Integrated Diagnostics Holdings's Debt-to-EBITDA or its related term are showing as below:
LSE:IDHC'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.27 Med: 0.45 Max: 3.52
Current: 3.52
During the past 13 years, the highest Debt-to-EBITDA Ratio of Integrated Diagnostics Holdings was 3.52. The lowest was 0.27. And the median was 0.45.
LSE:IDHC's Debt-to-EBITDA is ranked worse than 69.03% of 113
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.32
vs LSE:IDHC: 3.52
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Integrated Diagnostics Holdings Debt-to-EBITDA Related Terms
Integrated Diagnostics Holdings Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:IDHC vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Integrated Diagnostics Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Diagnostics Holdings Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integrated Diagnostics Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Integrated Diagnostics Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Integrated Diagnostics Holdings (LSE:IDHC) has a Debt-to-EBITDA of 0.00 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Integrated Diagnostics Holdings. Over the past decade, Integrated Diagnostics Holdings' Debt-to-EBITDA has ranged from 0.27 to 3.52. According to the industry distribution chart, Integrated Diagnostics Holdings ranks #78 out of 113 companies in the Medical Diagnostics & Research industry, placing it in the top 69%.
Is Integrated Diagnostics Holdings' Debt-to-EBITDA too high?
Integrated Diagnostics Holdings' current Debt-to-EBITDA is 0.00. Over the past 10 years, this metric has ranged from a low of 0.27 to a high of 3.52. Based on the distribution chart, Integrated Diagnostics Holdings ranks #78 out of 113 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Integrated Diagnostics Holdings has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Integrated Diagnostics Holdings' Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integrated Diagnostics Holdings ranks #78 out of 113 companies for Debt-to-EBITDA. This places Integrated Diagnostics Holdings in the lower half of its industry. The industry median Debt-to-EBITDA is 2.32. Historically, Integrated Diagnostics Holdings' own Debt-to-EBITDA has ranged from 0.27 to 3.52 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.32, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Integrated Diagnostics Holdings. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrated Diagnostics Holdings's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings (LSE:IDHC) is currently considered Fairly Valued. The stock's GF Value™ is $0.59, compared to a current price of $0.55 — trading 6.8% below its estimated fair value. The current Debt-to-EBITDA is 0.00. Integrated Diagnostics Holdings' overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Integrated Diagnostics Holdings (LSE:IDHC), the current Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Diagnostics Holdings (LSE:IDHC) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings stock appears to be undervalued.
The current stock price of $0.55 is trading 6.8% below its estimated GF Value™ of $0.59.
GuruFocus considers Integrated Diagnostics Holdings to be Fairly Valued.
Key valuation signals for LSE:IDHC:
Debt-to-EBITDA: 0.00
GF Value™: $0.59 vs. price of $0.55 (6.8% below fair value)
No single metric tells the full story. See the LSE:IDHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Diagnostics Holdings Business Description
Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider, operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan, Echo-Lab in Nigeria, and Biolab KSA in Saudi Arabia. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segments: the Contract Segment, which generates key revenue, and the Walk-in Segment. It derives a majority of its revenue from services offered in Egypt.
58GF Score
Get the complete analysis for LSE:IDHC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:IDHC has been successfully added to your 
